Role of cyclooxygenase-2 in head and neck tumorigenesis
|Author:||Frejborg, Ellen1; Salo, Tuula1,2,3,4,5; Salem, Abdelhakim1,2|
1Department of Oral and Maxillofacial Diseases, Clinicum, University of Helsinki, 00014 Helsinki, Finland
2Translational Immunology Research Program (TRIMM), Research Program Unit (RPU), University of Helsinki, 00014 Helsinki, Finland
3Cancer and Translational Medicine Research Unit, University of Oulu, 90220 Oulu, Finland
4Medical Research Centre, Oulu University Hospital, 90220 Oulu, Finland
5Department of Pathology, Helsinki University Hospital (HUS), 00029 Helsinki, Finland
|Online Access:||PDF Full Text (PDF, 1.5 MB)|
|Persistent link:|| http://urn.fi/urn:nbn:fi-fe20201214100633
Multidisciplinary Digital Publishing Institute,
|Publish Date:|| 2020-12-14
The cyclooxygenase-2 (COX-2) is a potent enzyme that converts arachidonic acid to prostaglandins (PG), including PGE2, a key mediator of inflammation and angiogenesis. Importantly, COX-2 is activated in response to inflammatory stimuli, where it is also believed to promote the development and progression of head and neck cancers (HNC). COX-2 can mediate its protumorigenic effect through various mechanisms, such as inducing cell proliferation, inhibition of apoptosis, and suppressing the host’s immune response. Furthermore, COX-2 can induce the production of vascular endothelial growth factors, hence, promoting angiogenesis. Indeed, the ability of COX-2 inhibitors to selectively restrict the proliferation of tumor cells and mediating apoptosis provides promising therapeutic targets for cancer patients. Thus, in this comprehensive review, we summarized the reported differential expression patterns of COX-2 in different stages of head and neck carcinogenesis—from potentially premalignant lesions to invasive carcinomas. Furthermore, we examined the available meta-analysis evidence for COX-2 role in the carcinogenesis of HNC. Finally, further understanding of the biological processes of COX-2 and its role in orchestrating cell proliferation, apoptosis, and angiogenesis may give therapeutically beneficial insight to develop the management plan of HNC patients and improve their clinical outcomes.
International journal of molecular sciences
|Pages:||1 - 17|
|Type of Publication:||
A2 Review article in a scientific journal
|Field of Science:||
This research was funded by the Emil Aaltonen Foundation; Minerva Foundation Institute for Medical Research; Cancer Society of Finland; Sigrid Jusélius Foundation; Jane and Aatos Erkko Foundation; Helsinki University Central Hospital Research Funds.
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).